Fibulin-4 deficiency increases TGF-β signalling in aortic smooth muscle cells due to elevated TGF-β2 levels

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ramnath, N W M ^a   Hawinkels, L J A C ^b   Van Heijningen, P M ^a   Te Riet, L ^a   Paauwe, M ^b   Vermeij, M ^a   Danser, A H J ^a   Kanaar, R ^a   Ten Dijke, P ^b   Essers, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBULIN-4; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL; AORTA; BLOOD; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; DEFICIENCY; HUMAN; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; THORACIC AORTA; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; AORTA; AORTA, THORACIC; CELL PROLIFERATION; EXTRACELLULAR MATRIX PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84948459833     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16872     Document Type: Article

References (51)

1. Lindsay, M. E. & Dietz, H. C. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473, 308-316, doi: nature1014510.1038/nature10145 (2011).
2. Olsson, C., Thelin, S., Stahle, E., Ekbom, A. & Granath, F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 114, 2611-2618, doi: CIRCULATIONAHA.106.63040010.1161/CIRCULATIONAHA.106.630400 (2006).
3. Isselbacher, E. M. Thoracic and abdominal aortic aneurysms. Circulation 111, 816-828, doi: 10.1161/01.Cir.0000154569.08857.7a (2005).
4. Bunton, T. E. et al. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 88, 37-43 (2001).
5. Inamoto, S. et al. TGFβR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovasc Res 88, 520-529, doi: cvq23010.1093/cvr/cvq230 (2010).
6. Dietz, H. C. et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352, 337-339, doi: 10.1038/352337a0 (1991).
7. Wang, L. et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet 87, 701-707, doi: S0002-9297(10)00522-710.1016/j.ajhg.2010.10.006 (2010).
8. van de Laar, I. M. et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 43, 121-126, doi: ng.74410.1038/ng.744 (2011).
9. ten Dijke, P. & Arthur, H. M. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 8, 857-869, doi: nrm226210.1038/nrm2262 (2007).
10. Loeys, B. L. et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFβR1 or TGFβR2. Nat Genet 37, 275-281, doi: ng151110.1038/ng1511 (2005).
11. Neptune, E. R. et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33, 407-411, doi: 10.1038/ng1116 ng1116 (2003).
12. Hanada, K. et al. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res 100, 738-746, doi: 01.RES.0000260181.19449.9510.1161/01.RES.0000260181.19449.95 (2007).
13. Renard, M. et al. Altered TGFβ signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. Eur J Hum Genet 18, 895-901, doi: ejhg20104510.1038/ejhg.2010.45 (2010).
14. Renard, M. et al. Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD. Int J Cardiol 165, 314-321, doi: S0167-5273(11)00920-X10.1016/j.ijcard.2011.08.079 (2013).
15. Renard, M. et al. Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFβ2. Int J Cardiol 165, 584-587, doi: S0167-5273(12)01135-710.1016/j.ijcard.2012.09.029 (2013).
16. Merwin, J. R., Newman, W., Beall, L. D., Tucker, A. & Madri, J. Vascular cells respond differentially to transforming growth factors β 1 and β 2 in vitro. Am J Pathol 138, 37-51 (1991).
17. Erickson, L. K., Opitz, J. M. & Zhou, H. Lethal osteogenesis imperfecta-like condition with cutis laxa and arterial tortuosity in MZ twins due to a homozygous fibulin-4 mutation. Pediatr Dev Pathol 15, 137-141, doi: 10.2350/11-03-1010-CR.1 (2012).
18. Sawyer, S. L. et al. Longer term survival of a child with autosomal recessive cutis laxa due to a mutation in FBLN4. Am J Med Genet A 161A, 1148-1153, doi: 10.1002/ajmg.a.35827 (2013).
19. Kappanayil, M. et al. Characterization of a distinct lethal arteriopathy syndrome in twenty-two infants associated with an identical, novel mutation in FBLN4 gene, confirms fibulin-4 as a critical determinant of human vascular elastogenesis. Orphanet J Rare Dis 7, 61, doi: 1750-1172-7-6110.1186/1750-1172-7-61 (2012).
20. Huang, J. et al. Fibulin-4 deficiency results in ascending aortic aneurysms: a potential link between abnormal smooth muscle cell phenotype and aneurysm progression. Circ Res 106, 583-592, doi: CIRCRESAHA.109.20785210.1161/CIRCRESAHA.109.207852 (2010).
21. Chen, Q. et al. Fibulin-4 regulates expression of the tropoelastin gene and consequent elastic-fibre formation by human fibroblasts. Biochem J 423, 79-89, doi: BJ2009099310.1042/BJ20090993 (2009).
22. Horiguchi, M. et al. Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase. Proc Natl Acad Sci USA 106, 19029-19034, doi: 090826810610.1073/pnas.0908268106 (2009).
23. Brisset, A. C. et al. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Circ Res 100, 1055-1062, doi: 01.RES.0000262654.84810.6c10.1161/01.RES.0000262654.84810.6c (2007).
24. Hao, H. et al. Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Arterioscler Thromb Vasc Biol 22, 1093-1099 (2002).
25. Wang, J., Chen, H., Seth, A. & McCulloch, C. A. Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 285, H1871-1881, doi: 10.1152/ajpheart.00387.2003 00387.2003 (2003).
26. Lucas, C. et al. The autocrine production of transforming growth factor-β 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol 145, 1415-1422 (1990).
27. Arteaga, C. L. et al. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 92, 2569-2576, doi: 10.1172/JCI116871 (1993).
28. Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17, 3091-3100, doi: 10.1093/emboj/17.11.3091 (1998).
29. Hawinkels, L. J. et al. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. Oncogene 33, 97-107, doi: 10.1038/onc.2012.536 (2014).
30. Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121, doi: 312/5770/11710.1126/science.1124287 (2006).
31. Moltzer, E. et al. Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade. PLoS One 6, e23411, doi: 10.1371/journal.pone.0023411 PONE-D-10-06286 (2011).
32. Tsai, S. et al. TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol 297, H540-549, doi: 91478.200710.1152/ajpheart.91478.2007 (2009).
33. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359, 693-699, doi: 10.1038/359693a0 (1992).
34. Kaartinen, V. et al. Abnormal lung development and cleft palate in mice lacking TGF-β 3 indicates defects of epithelialmesenchymal interaction. Nat Genet 11, 415-421, doi: 10.1038/ng1295-415 (1995).
35. Bartram, U. et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-β(2)-knockout mice. Circulation 103, 2745-2752 (2001).
36. Gallo, E. M. et al. Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest 124, 448-460, doi: 6966610.1172/JCI69666 (2014).
37. Battegay, E. J., Raines, E. W., Seifert, R. A., Bowen-Pope, D. F. & Ross, R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63, 515-524, doi: 0092-8674(90)90448-N (1990).
38. Jacobsen, S. E. et al. Bidirectional effects of transforming growth factor β (TGF-β) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-β isoforms. Blood 78, 2239-2247 (1991).
39. Lopez-Casillas, F., Wrana, J. L. & Massague, J. Betaglycan presents ligand to the TGF β signaling receptor. Cell 73, 1435-1444, doi: 0092-8674(93)90368-Z (1993).
40. Bee, K. J., Wilkes, D. C., Devereux, R. B., Basson, C. T. & Hatcher, C. J. TGFβRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor β2 signal transduction. Circ Cardiovasc Genet 5, 621-629, doi: CIRCGENETICS.112.96406410.1161/CIRCGENETICS.112.964064 (2012).
41. McCaffrey, T. A. et al. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β1. J Clin Invest 96, 2667-2675, doi: 10.1172/JCI118333 (1995).
42. Samarakoon, R., Overstreet, J. M. & Higgins, P. J. TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal 25, 264-268, doi: S0898-6568(12)00283-510.1016/j.cellsig.2012.10.003 (2013).
43. Fuchshofer, R. & Tamm, E. R. The role of TGF-β in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res 347, 279-290 doi: 10.1007/s00441-011-1274-7 (2012).
44. Jaschinski, F. et al. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2. Curr Pharm Biotechnol 12, 2203-2213 doi: BSP/CPB/E-Pub/000238-12-16(2011).
45. Hawinkels, L. J. & Ten Dijke, P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 29, 140-152, doi: 10.3109/08977194.2011.595411 (2011).
46. Brooke, B. S. et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358, 2787-2795, doi: 358/26/278710.1056/NEJMoa0706585 (2008).
47. Kuang, S. Q. et al. Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. Arterioscler Thromb Vasc Biol 33, 2172-2179, doi: ATVBAHA.113.30162410.1161/ATVBAHA.113.301624 (2013).
48. Massam-Wu, T. et al. Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF β. J Cell Sci 123, 3006-3018, doi: jcs.07343710.1242/jcs.073437 (2010).
49. Hawinkels, L. J. et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44, 1904-1913 doi: S0959-8049(08)00456-510.1016/j.ejca.2008.06.031 (2008).
50. Kaijzel, E. L. et al. Multimodality imaging reveals a gradual increase in matrix metalloproteinase activity at aneurysmal lesions in live fibulin-4 mice. Circ Cardiovasc Imaging 3, 567-577, doi: CIRCIMAGING.109.93309310.1161/CIRCIMAGING.109.933093 (2010).
51. Hawinkels, L. J. et al. Active TGF-β1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 100, 663-670 (2009).